Publication rates and reported results in a cohort of gene- and cell-based therapy trials

Delphi G. M. Coppens; Helga Gardarsdottir; Cornelis A. van den Bogert; Marie L. De Bruin; Hubert G. M. Leufkens; Jarno Hoekman

doi:10.2217/rme-2019-0066

Publication rates and reported results in a cohort of gene- and cell-based therapy trials

Delphi G. M. Coppens, Helga Gardarsdottir, Cornelis A. van den Bogert, Marie L. De Bruin, Hubert G. M. Leufkens, Jarno Hoekman

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Aim: We investigated publication rates and reported results for gene-and cell-based therapy trials. Materials & methods: In a cohort of Institutional Review Board (IRB)-authorized trials during 2007-2017 in the Netherlands (n = 105), we examine publication rates and reported results in scientific papers and conference abstracts as well as associations with the occurrence of trial characteristics. Results: The publication rate for scientific papers was 27% and 17% for conference abstracts (median survival time: 1050 days). Academic hospitals published more in scientific papers whereas private sponsors published more in conference abstracts. Manufacturing protocols were underreported compared with clinical outcomes. Most publications reported positive results (78%). Conclusion: Publication rates are currently suboptimal indicating a need for enhanced knowledge sharing to stimulate gene-and cell-based therapy development.

Original language	English
Pages (from-to)	1215-1227
Number of pages	13
Journal	Regenerative Medicine
Volume	15
Issue number	1
DOIs	https://doi.org/10.2217/rme-2019-0066
Publication status	Published - Feb 2020

Keywords

academic research
clinical trial cohort
clinical trial transparency
commercial development
conference abstract
drug regulatory science
gene-and cell-based therapies
publication bias
scientific publication

Access to Document

10.2217/rme-2019-0066

Cite this

@article{9633973c76a6410b989be4e5509f4fde,

title = "Publication rates and reported results in a cohort of gene- and cell-based therapy trials",

abstract = "Aim: We investigated publication rates and reported results for gene-and cell-based therapy trials. Materials & methods: In a cohort of Institutional Review Board (IRB)-authorized trials during 2007-2017 in the Netherlands (n = 105), we examine publication rates and reported results in scientific papers and conference abstracts as well as associations with the occurrence of trial characteristics. Results: The publication rate for scientific papers was 27% and 17% for conference abstracts (median survival time: 1050 days). Academic hospitals published more in scientific papers whereas private sponsors published more in conference abstracts. Manufacturing protocols were underreported compared with clinical outcomes. Most publications reported positive results (78%). Conclusion: Publication rates are currently suboptimal indicating a need for enhanced knowledge sharing to stimulate gene-and cell-based therapy development.",

keywords = "academic research, clinical trial cohort, clinical trial transparency, commercial development, conference abstract, drug regulatory science, gene-and cell-based therapies, publication bias, scientific publication",

author = "Coppens, {Delphi G. M.} and Helga Gardarsdottir and {van den Bogert}, {Cornelis A.} and {De Bruin}, {Marie L.} and Leufkens, {Hubert G. M.} and Jarno Hoekman",

year = "2020",

month = feb,

doi = "10.2217/rme-2019-0066",

language = "English",

volume = "15",

pages = "1215--1227",

journal = "Regenerative Medicine",

issn = "1746-0751",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Publication rates and reported results in a cohort of gene- and cell-based therapy trials

AU - Coppens, Delphi G. M.

AU - Gardarsdottir, Helga

AU - van den Bogert, Cornelis A.

AU - De Bruin, Marie L.

AU - Leufkens, Hubert G. M.

AU - Hoekman, Jarno

PY - 2020/2

Y1 - 2020/2

N2 - Aim: We investigated publication rates and reported results for gene-and cell-based therapy trials. Materials & methods: In a cohort of Institutional Review Board (IRB)-authorized trials during 2007-2017 in the Netherlands (n = 105), we examine publication rates and reported results in scientific papers and conference abstracts as well as associations with the occurrence of trial characteristics. Results: The publication rate for scientific papers was 27% and 17% for conference abstracts (median survival time: 1050 days). Academic hospitals published more in scientific papers whereas private sponsors published more in conference abstracts. Manufacturing protocols were underreported compared with clinical outcomes. Most publications reported positive results (78%). Conclusion: Publication rates are currently suboptimal indicating a need for enhanced knowledge sharing to stimulate gene-and cell-based therapy development.

AB - Aim: We investigated publication rates and reported results for gene-and cell-based therapy trials. Materials & methods: In a cohort of Institutional Review Board (IRB)-authorized trials during 2007-2017 in the Netherlands (n = 105), we examine publication rates and reported results in scientific papers and conference abstracts as well as associations with the occurrence of trial characteristics. Results: The publication rate for scientific papers was 27% and 17% for conference abstracts (median survival time: 1050 days). Academic hospitals published more in scientific papers whereas private sponsors published more in conference abstracts. Manufacturing protocols were underreported compared with clinical outcomes. Most publications reported positive results (78%). Conclusion: Publication rates are currently suboptimal indicating a need for enhanced knowledge sharing to stimulate gene-and cell-based therapy development.

KW - academic research

KW - clinical trial cohort

KW - clinical trial transparency

KW - commercial development

KW - conference abstract

KW - drug regulatory science

KW - gene-and cell-based therapies

KW - publication bias

KW - scientific publication

UR - http://www.scopus.com/inward/record.url?scp=85082145335&partnerID=8YFLogxK

U2 - 10.2217/rme-2019-0066

DO - 10.2217/rme-2019-0066

M3 - Article

SN - 1746-0751

VL - 15

SP - 1215

EP - 1227

JO - Regenerative Medicine

JF - Regenerative Medicine

IS - 1

ER -

Publication rates and reported results in a cohort of gene- and cell-based therapy trials

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this